Ann: Noxopharm Investigating Potential COVID-19 Treatment, page-19

A great announcement from NOX, I consider them reputable and this is a left field bonus to the underlying value in their very promising cancer treatments. they were arguably undervalued, although cash poor. I expect this opportunity may quickly find partners on a non dilutive basis given the urgency of large pharmas and governments to seek treatment options.
at 27c the market cap is sub $40m, this is minuscule given their cancer opportunity, let alone the Covid upside.
I hope they are successful from both a financial and moral view.